Fluocinolone acetonide intravitreal implant (Iluvien) Gets FDA Approval for Treating Diabetic Macular Edema (DME)

The Food and Drug Administration has approved fluocinolone acetonide intravitreal implant (Iluvien) as treatment for diabetic macular edema (DME), an eye condition characterized by swelling in the back of the retina that can lead to vision impairment or even blindness. DME is a complication of diabetes.

 
Iluvien, manufactured by Alimera Sciences Inc. and pSivida Corp., is an injectable implant. The treatment involves positioning a tiny, cylindrical tube containing a drug on the back of the eye – the spot where DME typically forms. Iluvien is expected to launch early next year. The treatment is already approved in 10 European countries, including the UK, France and Germany.
 
Source: Reuters